63.66

0.16% 0.10

After Hours: 63.45 -0.21 -0.33%

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $63.66, with a volume of 1.13M. It is up +0.16% in the last 24 hours and down -19.86% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$63.56

Open:

$64.31

24h Volume:

1.13M

Relative Volume:

0.57

Market Cap:

$7.51B

Revenue:

$947.36M

Net Income/Loss:

$392.47M

P/E Ratio:

21.08

EPS:

3.02

Net Cash Flow:

$392.71M

1W Performance:

-5.51%

1M Performance:

-19.86%

6M Performance:

-17.22%

1Y Performance:

+4.26%

1-Day Range:

$63.22

$64.58

1-Week Range:

$63.22

$68.40

52-Week Range:

$47.50

$82.22

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1116)

Industry

Biotechnology (621)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

423

Twitter

@halozymeinc

Next Earnings Date

2025-02-18

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	63.66	7.51B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-10-25	Resumed	Goldman	Neutral
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

07:02 AM

Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility - simplywall.st

07:02 AM

03:24 AM

Halozyme Therapeutics Receives 'Hold' Rating from Analysts - National Today

03:24 AM

Mar 13, 2026

Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness - finance.yahoo.com

Mar 13, 2026

Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - simplywall.st

Mar 13, 2026

Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India

Mar 13, 2026

Mar 12, 2026

Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com

Mar 12, 2026

Halozyme (HALO) Appoints David Ramsay as Interim CFO - GuruFocus

Mar 12, 2026

Halozyme (HALO) Appoints Interim CFO Amid Search for Permanent E - GuruFocus

Mar 12, 2026

Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PR Newswire

Mar 12, 2026

Capital Fund Management Boosts Stake in Halozyme Therapeutics - National Today

Mar 12, 2026

Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Mar 12, 2026

Mar 11, 2026

Halozyme at Citizens Life Sciences: Strategic Growth and Innovations By Investing.com - Investing.com Nigeria

Mar 11, 2026

Halozyme at Citizens Life Sciences: Strategic Growth and Innovations - Investing.com

Mar 11, 2026

Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock - Benzinga

Mar 11, 2026